‘TO USE ADOPTIVE CELL TRANSFERRING THERAPY’

“Our operation goal in 2022 is finishing the initial public offering (IPO), and we will take several actions to reach the goal. First of all, to increase the revenue, we constantly apply for operating permission from the Ministry of Health and Welfare (MOHW) to our adoptive cell transferring therapy, including CIKs-based therapy (cooperated with Kaohsiung Medical University ChungHo Memorial Hospital) against gastric and colorectal cancer and next generation TCR gamma delta T cell therapy. We have applied for permission for CIKs-based gastric and colorectal cancer therapy. In addition, we will file the immuno-profiling platform and CTCs detection method as Laboratory Developed Tests (LDTs). Finally, we will establish branch offices in Japan to expand business in Japan. Second, we aim to perform clinical trials for verifying the safety and anti-cancer efficacy of our cell products, PHYDUXON, next generation TCR gamma delta T cells, and EBaT8.”

- JAN-MOU LEE, General Manager, FullHope Biomedical, Taiwan